Celcuity Forecasts $2.5B Peak Revenue for Gedatolisib Celcuity projects $2.5B peak revenue for gedatolisib with pivotal readouts in 2026–27 and commercial steps underway (Seeking Alpha, Mar 26, 2026).

Celcuity Forecasts $2.5B Peak Revenue for Gedatolisib: Celcuity projects $2.5B peak revenue for gedatolisib with pivotal readouts in 2026–27 and commercial steps underway (Seeking Alpha, Mar 26, 2026). 👈 Read full analysis #Celcuity #Gedatolisib #Pharmaceuticals #Biotechnology #MarketForecast

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer PURPOSEGedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials w...

Adición de Gedatolisib a fulvestrant, con o sin palbociclib, reduce riesgo de progresión de enf o muerte en pac c/CA mama avanzado PIK3CS salvaje, HR+ HER2- #gedatolisib #breastcancer ascopubs.org/doi/full/10....